127TiP An open-label, randomized, multicenter, phase III study of trastuzumab deruxtecan (T-DXd) with bevacizumab (BEV) vs BEV monotherapy as first-line (1L) maintenance therapy in HER2-expressing ovarian cancer: DESTINY-Ovarian01 (DO 01)
A. González-Martín, Jo Marie Tran Janco, June‐Yong Lee, Domenica Lorusso, Sven Mahner, K.N. Moore, D.S. Tan, Veronica Mariotti, Jared H. Hara, Shao‐Ying Hua, J.F. Liu, Kazuki Hasegawa
Abstract
Patients (pts) with HER2-expressing ovarian cancer (OC), representing up to ∼30%-40% of all OC, face a poor prognosis characterized by advanced disease stages, higher recurrence rates, and shorter survival times, highlighting a significant unmet need in this population. In the single-arm DESTINY-PanTumor02 study, T-DXd monotherapy demonstrated antitumor activity in heavily pretreated pts with OC (Meric-Bernstam F et al. J Clin Oncol. 2023). Preclinical data in OC models have also shown that combining T-DXd with BEV significantly enhances antitumor activity vs either therapy alone.